A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Trial Details

NCT ID
NCT05961111
Phase
EARLY_PHASE1
Sponsor
Shanghai Yunying Medical Technology
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Recombinant oncolytic herpes simplex virus type 1 (R130)
Locations (sample)
  • Linyi, Shandong, China|35.06306,118.34278

Key Eligibility Criteria

  • Patients with solid tumors clearly diagnosed by histology and/or cytology.
  • Failure of standard treatment or patient unwillingness to receive other antitumor therapy.
  • Age 18 to 75 years.
  • Subjects with ECoG score of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →